Gastrointestinal side effects of high-dose GLP-1 RAs and co-agonists occurred in 30%-70% of patients, mostly arising within the first 2 weeks of the first dose, being mild or moderate in severity, and transient [28]
Here are some steps you should take: Regular Check-Ups: Schedule regular appointments with your doctor to monitor your condition
That will require larger, dedicated randomized trials in addiction, targeted studies in pain syndromes beyond knee osteoarthritis, longer-term musculoskeletal safety data, and honest communication about both the promise and the risks of GLP-1s
However, GLP-1/GIP products are often more complex than they may seem at first glance
groups included were the control group, ifosfamide group, ifosfamide plus Mesna, and ifosfamide or gingerol